theory clinical_2_9
imports Main

begin

typedecl entity
typedecl event

consts
  SyntheticLethality :: "entity ⇒ bool"
  GeneticEvents :: "entity ⇒ bool"
  LossOfBRCA2 :: "entity ⇒ bool"
  Occurs :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  CoOccurrence :: "event ⇒ bool"
  Result :: "event ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  InabilityToRepair :: "event ⇒ bool"
  DNA :: "entity ⇒ bool"
  Through :: "event ⇒ entity ⇒ bool"
  MultiplePathways :: "entity ⇒ bool"
  PARPInhibitors :: "entity ⇒ bool"
  DoubleStrandBreaks :: "entity ⇒ bool"
  SingleStrandBreakRepair :: "entity ⇒ bool"
  Cells :: "entity ⇒ bool"
  Cause :: "event ⇒ bool"
  Prevent :: "event ⇒ bool"
  Force :: "event ⇒ bool"
  Rely :: "event ⇒ bool"
  On :: "event ⇒ entity ⇒ bool"
  DefectiveHomologousRecombinationRepair :: "entity ⇒ bool"
  ErrorProneNonHomologousEndJoining :: "entity ⇒ bool"
  Repair :: "event ⇒ bool"
  BRCA2Loss :: "entity ⇒ bool"
  Mechanism :: "entity ⇒ bool"
  CumulativeDNADamage :: "entity ⇒ bool"
  PrimaryRepairPathways :: "event ⇒ bool"
  Compromised :: "event ⇒ bool"
  Lead :: "event ⇒ bool"
  To :: "event ⇒ entity ⇒ bool"
  IncreasedRelianceOnAlternativeRepairMechanisms :: "entity ⇒ bool"
  Patients :: "entity ⇒ bool"
  PARP1Inhibition :: "entity ⇒ bool"
  Benefit :: "event ⇒ bool"
  Source :: "event ⇒ entity ⇒ bool"
  CumulativeDamage :: "entity ⇒ bool"

(* Explanation 1: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways. *)
axiomatization where
  explanation_1: "∃x y z e1 e2 e3 e4. SyntheticLethality x ∧ GeneticEvents y ∧ LossOfBRCA2 z ∧ Occurs e1 ∧ Agent e1 x ∧ CoOccurrence e2 ∧ Agent e2 y ∧ Result e3 ∧ Agent e3 y ∧ Patient e3 z ∧ InabilityToRepair e3 ∧ DNA z ∧ Through e4 z ∧ Agent e4 z"

(* Explanation 2: PARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)
axiomatization where
  explanation_2: "∃x y z w e1 e2 e3 e4 e5 e6. PARPInhibitors x ∧ DoubleStrandBreaks y ∧ SingleStrandBreakRepair z ∧ Cells w ∧ Cause e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Prevent e2 ∧ Agent e2 x ∧ Patient e2 z ∧ Force e3 ∧ Agent e3 z ∧ Patient e3 w ∧ Rely e4 ∧ Agent e4 w ∧ On e5 w ∧ On e6 w ∧ Repair e5 ∧ Agent e5 w ∧ Patient e5 z"

(* Explanation 3: In the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised, leading to an increased reliance on alternative repair mechanisms. *)
axiomatization where
  explanation_3: "∃x y z w e1 e2 e3 e4 e5 e6. BRCA2Loss x ∧ SyntheticLethality y ∧ Cells z ∧ Mechanism w ∧ Cause e1 ∧ Agent e1 y ∧ Patient e1 z ∧ Rely e2 ∧ Agent e2 z ∧ On e2 w ∧ Repair e3 ∧ Agent e3 z ∧ Patient e3 e6 ∧ CumulativeDNADamage e6 ∧ PrimaryRepairPathways e4 ∧ Compromised e4 ∧ Lead e5 ∧ Agent e5 e4 ∧ To e5 IncreasedRelianceOnAlternativeRepairMechanisms"

theorem hypothesis:
  assumes asm: "Patients x ∧ LossOfBRCA2 x ∧ PARP1Inhibition y ∧ SyntheticLethality z ∧ Cells w"
  (* Hypothesis: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA *)
  shows "∃x y z w e1 e2 e3 e4. Patients x ∧ LossOfBRCA2 x ∧ PARP1Inhibition y ∧ SyntheticLethality z ∧ Cells w ∧ Benefit e1 ∧ Agent e1 x ∧ Source e1 y ∧ Cause e2 ∧ Agent e2 z ∧ Patient e2 w ∧ Rely e3 ∧ Agent e3 w ∧ Mechanism e3 ∧ Repair e4 ∧ Agent e4 w ∧ Patient e4 CumulativeDamage ∧ To e4 DNA"
proof -
  (* From the premise, we have known information about patients, loss of BRCA2, PARP1 inhibition, synthetic lethality, and cells. *)
  from asm have "Patients x ∧ LossOfBRCA2 x ∧ PARP1Inhibition y ∧ SyntheticLethality z ∧ Cells w" <ATP>
  
  (* Explanation 3 states that in the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage. *)
  (* This implies that with BRCA2 loss and synthetic lethality, cells rely on a singular mechanism. *)
  from explanation_3 have "BRCA2Loss x ∧ SyntheticLethality z ⟶ (Rely e3 ∧ Agent e3 w ∧ Mechanism e3)" <ATP>
  
  (* Since we have LossOfBRCA2 x and SyntheticLethality z from the premise, we can infer reliance on a singular mechanism. *)
  then have "Rely e3 ∧ Agent e3 w ∧ Mechanism e3" <ATP>
  
  (* Explanation 2 states that PARP inhibitors cause replication-associated double strand breaks, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining. *)
  (* This implies that PARP inhibitors lead to reliance on alternative repair mechanisms. *)
  from explanation_2 have "PARPInhibitors y ⟶ (Cause e2 ∧ Agent e2 z ∧ Patient e2 w ∧ Rely e3 ∧ Agent e3 w)" <ATP>
  
  (* Since we have PARP1Inhibition y from the premise, we can infer the cause and reliance on repair mechanisms. *)
  then have "Cause e2 ∧ Agent e2 z ∧ Patient e2 w ∧ Rely e3 ∧ Agent e3 w" <ATP>
  
  (* Combining these inferences, we can conclude that patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA. *)
  then have "Benefit e1 ∧ Agent e1 x ∧ Source e1 y ∧ Cause e2 ∧ Agent e2 z ∧ Patient e2 w ∧ Rely e3 ∧ Agent e3 w ∧ Mechanism e3 ∧ Repair e4 ∧ Agent e4 w ∧ Patient e4 CumulativeDamage ∧ To e4 DNA" <ATP>
  
  then show ?thesis <ATP>
qed

end
